Back |

MPI Research, a leader worldwide in preclinical drug discovery and development research, is honored to play an active role in the 6th annual meeting of the Safety Pharmacology Society, being held September 26-28, 2006 at the Town and Country Resort and Convention Center in San Diego, California. We are pleased to announce a timely program of poster presentations, detailing the recent efforts of MPI Research scientists on our Safety Pharmacology team:

• Validation of an ICH-compliant functional observational battery in nonhuman primates
• Validation of rodent self-administration procedures for abuse liability testing in a contract research organization
• Validation of rodent drug discrimination procedures for abuse liability testing in a contract research organization
• Simultaneous assessment of ECGs using intracardiac and subcutaneous leads under various environmental conditions in nonhuman primates
• Effects of cisapride, sotalol and haloperidol in a Langendorff assay and comparison to hERG, Purkinje fiber and in vivo telemetry assays
• Validation of methods to assess respiratory function in tandem with pleural pressure and diaphragm EMGs in conscious freely-moving nonhuman primates

Additionally, Drs. Ted Baird and David Gauvin and MPI Research surgeon David Moddrelle will be instructors in Continuing Education courses. “The Safety Pharmacology Society is highly valued as a forum to share and advocate best practices in the field of safety pharmacology,” says MPI Research’s Director of Safety Pharmacology, Ted Baird, PhD. “We are gratified to contribute to this process by exhibiting, educating, and presenting some of our recent and exciting research.”

MPI Research focuses on quality and timeliness in providing comprehensive preclinical research, from early proof of concept testing to regulatory submissions. Because of increased demands for its scientific expertise and broad scope of services, MPI Research is upgrading and expanding its facilities on its 130-acre site. Yet at MPI Research, the service commitment goes beyond the state-of-the-art facilities and innovative processes. The company values results, and its team of 1,100+ employees efficiently create and implement standardized and custom GLP research programs within the broad areas of toxicology, pathology, efficacy, and safety pharmacology. Known for its proactive problem-solving capabilities, MPI Research is proud of its reputation as being the best in its field.

Visit MPI Research at booth #4 at this prestigious meeting (www.safetypharmacology.org/meeting) or at www.mpiresearch.com to learn how we can assist you in bringing safer, better pharmaceutical, biopharmaceutical, and healthcare products to the world.

Home | News